HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 101 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού; June 30, 2020 New analysis reveals Black women in England more likely to be... January 27, 2023 Vulnerability in Brain Tumors May Open Door to New Treatments September 26, 2022 How Breast Cancer Risk Assessment Tools Work June 27, 2024 Load more HOT NEWS Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions Easing Concerns about Giving Research Study Participants Their Genetic Test Results Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side...
